The decision to enter the settlement was made so that we could avoid the expense and the distraction that's often associated with potentially protracted litigation.

250

These studies that are referenced in the new labeling are largely updated analyses from the data that was the justification for the change in September.

185

We made the decision that settling was appropriate to avoid the expense and distraction of protracted litigation.

141

We obviously have worked with the FDA and we're moving forward to make this information available to health care professionals and patients so that informed treatment decisions can be made.

130

It raises awareness and encourages them to seek medical attention if they think they have a particular disease.

76